Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners began coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a report published on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $16.00 target price on the stock.

Several other research analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Atyr PHARMA presently has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Stock Up 11.1 %

Atyr PHARMA stock opened at $3.79 on Tuesday. The firm has a market cap of $318.13 million, a PE ratio of -4.03 and a beta of 1.10. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The firm’s 50 day moving average price is $3.55 and its two-hundred day moving average price is $2.83. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.22.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ATYR. JPMorgan Chase & Co. raised its stake in shares of Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after acquiring an additional 10,754 shares in the last quarter. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA in the fourth quarter valued at approximately $36,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of Atyr PHARMA in the fourth quarter worth $170,000. American Century Companies Inc. bought a new stake in shares of Atyr PHARMA during the 4th quarter worth $319,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA during the 4th quarter worth $39,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.